Dapagliflozin gets PBAC nod for HFrEF
But a bid to subsidise the agent for chronic kidney disease in the wake of favourable studies has been rejected
Dapagliflozin could soon be PBS listed as a treatment for heart failure with reduced ejection fraction following a recommendation by the PBAC.
The committee says it is satisfied that the SGLT2 inhibitor, in combination with existing therapy, provides “a significant improvement in efficacy over standard care alone”.
